CD8A and neoplasm: BCL6 has been shown to promote the development and maintenance of tumor-associated stem/progenitor-like CD8+ T cells associated with the persistence of anti-tumor responses [127], providing sustained anti-tumor immunity in the context of lung cancer [128] and melanoma [128,129].